Christine N. Kay, MD, discussed her presentation, "Deuterated vitamin A preserves vision in Stargardt’s disease (TEASE study) ...

Thomas Aaberg, Jr, MD, Neurotech's Chief Medical Officer, shared some insights on the company's recent presentation as well ...

Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease.

Ferhina S. Ali, MD, MPH, discusses how to effectively manage geographic atrophy by considering treatment timing, utilizing imaging modalities, analyzing phase 3 trial data, and developing personalized ...

Ferhina S. Ali, MD, MPH, discusses the management of progressive geographic atrophy in an 84-year-old man, focusing on the significance of patient education in optimizing treatment outcomes and ...

R. Theodore Smith, MD, PhD, Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai, New York, reported that cardiac arrhythmias such as atrial fibrillation are associated with ...

A team of researchers at the Ohio State University found that in mice an enzyme related to cell growth and division is a culprit in the blood vessel invasion in the back of the eye that causes blurred ...

MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.

Ferhina S. Ali, MD, MPH, discusses how emerging treatments and tailored management strategies can improve the care of patients with geographic atrophy in age-related macular degeneration, emphasizing ...

The annual American Academy of Ophthalmology meeting will include notable data and announcements for many companies in the ophthalmic space as they discuss upcoming and ongoing clinical trials as well ...

João Pedro Marques, MD, MSc, PhD, FEBOphth, and colleagues investigated the genetic spectrum of retinal dystrophy and hearing loss in Portugal. While Usher syndrome is the most common cause, he and ...

Dilsher Dhoot, MD, sat down with Modern Retina to provide some insights on the phase 1 HELIOS trial, which he presented on during the 2024 ASRS meeting held in Stockholm, Sweden earlier in 2024.